Quick Answer
Design Therapeutics, Inc. reported Research And Development Expense of $59.13 million for the year ending 2025.
- Design Therapeutics, Inc. showed an increase of +33.3% in Research And Development Expense from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $377.0 thousand | Q2 2020: $1.06 million | Q3 2020: $1.91 million | Q1 2021: $3.88 million | Q2 2021: $5.03 million | Q3 2021: $8.54 million | Q1 2022: $8.76 million | Q2 2022: $11.30 million | Q3 2022: $14.30 million | Q1 2023: $15.73 million | Q2 2023: $17.06 million | Q3 2023: $13.26 million | Q1 2024: $9.80 million | Q2 2024: $10.52 million | Q3 2024: $11.88 million | Q1 2025: $15.38 million | Q2 2025: $15.74 million | Q3 2025: $14.59 million.
- Over the full 6 years of available data (2020 to 2025), Design Therapeutics, Inc.'s Research And Development Expense has grown by 875.7%.
- Historical annual values: Fiscal year 2025: $59.13 million | Fiscal year 2024: $44.35 million | Fiscal year 2023: $57.06 million | Fiscal year 2022: $48.61 million | Fiscal year 2021: $24.78 million | Fiscal year 2020: $6.06 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: